Apixaban: Evaluation of the Inclusion of Studies Identified by the FDA as Having Falsified Data in the Results of Meta-analyses: The Example of the Apixaban Trials | Research, Methods, Statistics | JAMA Internal Medicine | JAMA NetworkIn our reanalysis of the 22 meta-analyses, we found that 10 (46%) yielded results that would change the initial meta-analysis findings. Each affected meta-analysis had a median of 9.5 publications (range, 2-17), and the median meta-analysis publication InCite journal impact factor was 5.830 (range, 3.154-17.202). The median weight of publications with falsified data was 55.7% (range, 13.1%-99.6%). From our reanalysis of the 22 meta-analyses, we found that 32 of 99 analyses (32%) yielded results that would change the conclusions of the initial analysis (Table). Of the 32 affected estimates, 31 (97%) no longer favored apixaban for the prevention of serious medical issues, and 1 (3%) favored the control.